760
B. Huet al. / Bioorg. Med. Chem. Lett. 11 (2001) 757–760
5. Svensson, M.; Helgee, B.; Bertil, K.; Andersson, G. J.
Mater. Chem. 1998, 8, 353.
Acknowledgements
6. For the synthesis of 7 and 8a, see: Washburn, W. N.;
Girotra, R. N.; Sher, P. M.; Mikkilineni, A. B.; Poss, K. M.;
Mathur, A.; Gavai, A.; Bisacchi, G. S. EP 659737, 1995;
Chem. Abstr. 1995, 124, 8408
The authors acknowledge the members of the Wyeth-
Ayerst Discovery Analytical Chemistry group for ana-
lytical and spectral determinations.
7. Alvarez, S. G.; Alvarez, M. T. Synthesis 1997, 413.
8. Oelschlaeger, H.; Schreiber, O. Liebigs Ann. Chem. 1961,
641, 81.
References and Notes
9. Guy, A.; Ferroud, D. C.; Garreay, R.; Godefroy-Fal-
guieres, A. Synthesis 1992, 821.
10. Sarodnick, G.; Kempter, G. Pharmazier 1985, 40, 384.
11. Taylor, E. C.; Skotnicki, J. S. Synthesis 1981, 606.
12. All final compounds and novel aryloxypropanolamines
1. (a) For recent reviews on b3-agonists see: Katsilambros, N.
Eur. J. Intern. Med. 2000, 11, 65. (b) Weyer, C.; Gautier, J. F.;
Danforth, E., Jr. Diabetes Metab. 1999, 25, 11. (c) Kordik,
C. P.; Reitz, A. B. J. Med. Chem. 1999, 42, 181. (d) Weber,
A. E. Annu. Rep. Med. Chem. 1998, 33, 193. (e) Dow, R. L.
Exp. Opin. Invest. Drugs 1997, 6, 1811.
2. (a) Sum, F. W.; Gilbert, A.; Venkatesan, A. M.; Lim, K.;
Wong, V.; O’Dell, M.; Francisco, G.; Chen, Z.; Grosu, G.;
Baker, J.; Ellingboe, J.; Malamas, M.; Gunawan, I.; Primeau,
J.; Largis, E.; Steiner, K. Bioorg. Med. Chem. Lett. 1999, 9,
1921. (b) Bloom, J. D.; Dutia, M. D.; Johnson, B. D.; Wissner,
A.; Burns, M. G.; Largis, E. E.; Dolan, J. A.; Claus, T. H. J.
Med. Chem. 1992, 35, 3081. (c) Hu, B. Unpublished results.
3. (a) For the synthesis of 4b and 4f see: Siegel, M. G.; Shu-
ker, A. J.; Droste, C. A.; Hahn, P. J.; Jesudason, C. D.;
Mcdonald, J. H., III; Matthews, D. P.; Rito, C. J.; Thorpe, A.
J. Mol. Div. 1998, 3, 113. (b) Bell, M. G.; Crowell, T. A.;
Matthews, D. P.; McDonald, J. H., III; Nee, D. A.; Shuker,
A. J.; Winter, M. A. U.S. Patent 708,621, 1998; Chem. Abstr.
1998, 129, 148910.
1
and arylethanolamines were characterized by H NMR, mass
spectrometry, and high-resolution mass spectrometry. All
of the compounds that are being biologicallyevaluated are
mixtures of diastereomers (the 2,4-thiazolidinedione adds a
chiral center to the structure). For experimental details, see:
Hu, B.; Sum, F.-W.; Malamas, M. PCT application, sub-
mitted, July, 2000.
13. The human b3 receptor was cloned as described in Van,
S. A.; Nahmias, C. K. S.; Briend-Sutren, M. M.; Strosberg,
A. D.; Emorine, L. J. Eur. J. Biochem. 1993, 213, 1117. The
human b2 and b1 receptors were cloned as described in Tate,
K. M.; Briend-Sutren, M. M.; Emorine, L. J.; Delavier-
Klutchko, C.; Marullo, S.; Strosberg, A. D. Eur. J. Biochem.
1993, 196, 357.
14. For radioligand binding procedure see: Zheng, W.; Niku-
lin, V. I.; Konkar, A. A.; Vansal, S. S.; Shams, G.; Feller,
D. R.; Miller, D. D. J. Med. Chem. 1999, 42, 2287.
15. For measuring thermogenesis in human b3-AR transgenic
mice and b3-AR knock out mice see: Susulic, V. S.; Frederich,
R. C.; Lawitts, J.; Tozzo, E.; Khahn, B. B.; Harper, M.-E.;
Himms-Hagen, J.; Flier, J. S.; Lowell, B. B. J. Biol. Chem.
1995, 270, 29483.
4. Beeley, L. J.; Berge, J. M.; Chapman, H.; Dean, D. K.;
Kelly, J.; Lowden, K.; Kotecha, N. R.; Morgan, H. K. A.;
Rami, H. K.; Thompson, M.; Vong, A. K. K.; Ward,
R. W. Bioorg. Med. Chem. Lett. 1997, 7, 219 and references
therein.